Imagine a future where a simple injection could replace the need for liver transplants, offering hope to thousands of patients with chronic liver disease. This bold vision is not just a fantasy; it's a reality that MIT engineers are bringing to life.
In a groundbreaking study, researchers have developed "mini livers" that can be injected into the body, potentially revolutionizing the way we treat liver failure. But here's where it gets controversial: these mini livers might just eliminate the need for risky surgeries and long waitlists for donated organs.
More than 10,000 Americans are currently on the transplant waitlist, yet the supply of donated livers falls short. Many patients are also ineligible for transplants due to their overall health. To address this critical gap, MIT's innovative approach focuses on creating "satellite livers" that can step in and take over the failing organ's functions.
In a recent study on mice, the researchers demonstrated that these injected liver cells could survive and function for at least two months, producing essential enzymes and proteins. This breakthrough offers a glimmer of hope for patients with liver failure, providing a potential long-term treatment option.
"We envision these as satellite livers," explains Sangeeta Bhatia, a professor at MIT and a senior author of the study. "By delivering these cells into the body while leaving the sick organ in place, we can provide a boost to liver function."
The human liver is responsible for an astonishing 500 essential functions, from regulating blood clotting to metabolizing drugs. Most of these tasks are carried out by hepatocytes, specialized liver cells. Over the past decade, Bhatia's lab has been dedicated to restoring hepatocyte function without the need for surgical transplants.
One approach they've explored is embedding hepatocytes into a biomaterial like hydrogel, but this method still requires surgical implantation. The team's latest strategy involves injecting hepatocytes directly into the body, along with hydrogel microspheres that help the cells stay together and connect with nearby blood vessels.
These microspheres have unique properties that allow them to act like a liquid when packed closely, making them injectable through a syringe. Once inside the body, they regain their solid structure. In the past, researchers have used these microspheres to promote wound healing by helping cells migrate and build new tissue.
In this study, the MIT team adapted the technology to assist hepatocytes in forming a stable tissue graft after injection. "What we've done is create an engineered niche for cell transplantation," says Vardhman Kumar, the paper's lead author and a postdoc in Bhatia's lab.
The injected mixture also includes fibroblast cells, which support the hepatocytes and encourage the growth of blood vessels into the tissue. Working with ultrasound specialist Nicole Henning, the researchers developed a method to inject the cell mixture using ultrasound guidance, ensuring precision and accuracy.
In tests on mice, the researchers injected the mixture of liver cells and microspheres into perigonadal adipose tissue, a fatty area in the belly. Over time, new blood vessels grew into the graft area, supporting the health of the injected hepatocytes. "The new blood vessels formed right next to the hepatocytes, allowing them to receive nutrients and function properly," Kumar explains.
After injection, the cells remained viable and capable of secreting specialized proteins into the host's circulation for eight weeks, indicating the potential for long-term treatment. "This technology could provide an alternative to surgery and serve as a bridge to transplantation," Kumar suggests. "It could offer support until a donor organ becomes available, and the barriers to additional treatments or grafts are much lower with this injectable approach compared to surgery."
While the current version of the technology may require patients to take immunosuppressive drugs, the researchers are exploring the development of "stealthy" hepatocytes that can evade the immune system or using hydrogel microspheres to deliver immunosuppressants locally.
This innovative approach has the potential to transform the way we treat liver disease, offering a ray of hope to patients facing the challenges of chronic liver failure. The future of liver health might just be a simple injection away.
